Trial
NCT02026362
Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).
Phase ISUSPENDEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
HRYZ Biotech Co.
Collaborators
Nanfang Hospital, Southern Medical University; Third Affiliated Hospital, Sun Yat-Sen University; Sun Yat-sen University; Beijing 302 Hospital; Fujian Cancer Hospital
Condition
Hepatocellular Carcinoma
Intervention
MASCT:Multiple Antigens Specific Cellular Therapy
Why stopped
Interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-18